| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2/3 data readout example | PEDMARK (sodium thiosulfate injection) Pediatric and adolescent patients with non-metastatic solid tumors | Phase 2/3 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 2/3 data readout example | PEDMARK (sodium thiosulfate injection) Pediatric and adolescent patients with non-metastatic solid tumors | Phase 2/3 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 2/3 data readout example | PEDMARK (sodium thiosulfate injection) Pediatric and adolescent patients with non-metastatic solid tumors | Phase 2/3 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Fennec Pharmaceuticals Inc.
$11.35
-0.3 (-2.53%)
D 34Pipeline Score Overvalued Biotech · Clinical
Market Cap
397.91 M
EPS
-0.09
P/E Ratio
-
Value Trade
3.43 M
-3.16 %
Week
9.98 %
1 Month
14.3 %
3 Month
29.86 %
6 Month
44.33 %
5 Year
688.02 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
246.21 K
52 Week Range
5.65 - 13.25
% held by Insiders
14.54 %
% held by Institutions
54.54 %
Enterprise Value
356.66 M
Total Shares
35.06 M
Short %
2.05 %
Float Shares
22.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Fennec Pharmaceuticals Inc.
493Total events
3Upcoming
128Tier-1 (high impact)
2005 – 2026Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2FDA Feedback Received
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Product LaunchPEDMARKApprovedPost-Market
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2022-09-23 | Pedmark (sodium thiosulfate) | PDUFA Date | PDUFA | Approved | – | – | – |
2022-09-23 | Pedmark (sodium thiosulfate) | PDUFA Date | PDUFA | Approved | – | – | – |
2022-09-23 | Pedmark (sodium thiosulfate) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
D34
Pipeline Score $152M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.4x
rNPV / MCap Top 47%
Micro Cap (rank 494 of 931)
Percentile RankFennec Pharmaceuticals Inc. faces pipeline headwinds (34/100), with $379M risk-adjusted pipeline value, led by ADH-1 in Neoplasms (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADH-1 Small molecule | Neoplasms | Phase 2 | NCT00421811 | 19% | $246M | COMPLETED | 56 | - | - | Mar 1, 2009 | - | Dec 28, 2010 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PEDMARK® Orphan | reduction of cisplatin-induced hearing loss in pediatric and adolescent patients with non-metastatic solid tumors | Phase 2/3 | 2026-05-22 | In the Phase 2/3 STS-J01 trial, PEDMARK® significantly reduced cisplatin-induced hearing loss in pediatric and adolescent patients, with rates of hearing loss at 16-24% compared to 56-63% in historical controls (p<0.001). Read More | Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting Read More | |
PEDMARK® Orphan | reduction of cisplatin-induced hearing loss in pediatric and adolescent patients with non-metastatic solid tumors | Phase 2/3 | 2026-05-22 | In the Phase 2/3 STS-J01 trial, PEDMARK® significantly reduced cisplatin-induced hearing loss in pediatric and adolescent patients, with rates of hearing loss at 16-24% compared to 56-63% in historical controls (p<0.001). Read More | Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting Read More | |
PEDMARK® Orphan | reduction of cisplatin-induced hearing loss in pediatric and adolescent patients with non-metastatic solid tumors | Phase 2/3 | 2026-05-22 | In the Phase 2/3 STS-J01 trial, PEDMARK® significantly reduced cisplatin-induced hearing loss in pediatric and adolescent patients, with rates of hearing loss at 16-24% compared to 56-63% in historical controls (p<0.001). Read More | Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FENC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
FENC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
FENC▲ +16.8%on this news
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported a strong financial performance for the second quarter of 2026, with net product sales reaching $17.1 million, a 78% increase compared to the previous year. The company achieved a non-GAAP adjusted EBITDA of $2.8 million. Additionally, record demand for PEDMARK® is expected to continue into the third quarter, supported by ongoing field sales expansion efforts.
Read more →FENCFennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
Fennec Pharmaceuticals Inc. will announce its second quarter 2026 financial results on August 11, 2026, before U.S. market opening. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company is known for its commitment to reducing ototoxicity in cancer patients through its product PEDMARK, which has received various regulatory approvals.
Read more →FENCFennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fennec Pharmaceuticals announced the grant of incentive stock options to a new employee as part of its 2026 Equity Inducement Plan. The options, totaling 10,000 shares, have an exercise price of $9.00 and a ten-year term. The company continues to focus on its product PEDMARK/PEDMARQSI, which aims to reduce ototoxicity in patients undergoing chemotherapy and has received several regulatory approvals.
Read more →FENCFennec Announces Results of Annual Meeting
Fennec Pharmaceuticals Inc. held its Annual General and Special Meeting of Shareholders on June 10, 2025, announcing the election results of its board nominees. Notably, nearly all nominees received significant approval rates, with Dr. Khalid Islam achieving 97.84% of votes in favor. Shareholders also showed strong support for appointing auditors and approving executive compensation. The meeting addressed amendments to the Company’s 2020 Equity Incentive Plan, utilizing a TSX exemption for smoother execution.
Read more →FENCFennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
Fennec Pharmaceuticals announced new research on PEDMARK® at the 2026 ASCO Annual Meeting, highlighting its potential benefits for diverse patient populations. The studies demonstrate that PEDMARK® can be safely integrated into treatment regimens without compromising the efficacy of cisplatin. Results indicate significant reductions in cisplatin-induced hearing loss, particularly among pediatric and adolescent patients. The ongoing research reflects a commitment to addressing unmet needs in cancer survivorship.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) Research Triangle Park, NC
Fennec Pharmaceuticals has announced the grant of stock options to three new non-executive employees as an inducement under Nasdaq Listing Rule 5635(c)(4). The stock options, totaling 50,000 shares, are part of the company's 2026 Equity Inducement Plan, which aims to attract individuals who were not previously employees. Fennec continues to focus on its product PEDMARK, designed to combat ototoxicity in cancer patients, having achieved recent regulatory approvals in multiple regions.
Read more →FENC▲ +36.5%on this newsshared move
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported strong first-quarter financial results for 2026, with net revenues reaching $15.1 million, up 73% year-over-year. The company noted promising early trends from its field sales expansion and highlighted record demand for its product, PEDMARK, in April 2026. Additionally, Fennec has initiated a third clinical study evaluating PEDMARK in adolescent, young adult, and adult patients with head and neck and testicular cancers. Furthermore, four abstracts regarding PEDMARK will be presented at the 2026 ASCO Annual Meeting.
Read more →FENCFENNEC PHARMACEUTICALS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 14, 2026
Fennec Pharmaceuticals Inc. will announce its first quarter 2026 financial results on May 14, 2026, before U.S. market opening. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company focuses on reducing ototoxicity in cancer patients through its FDA-approved product, PEDMARK.
Read more →FENCFennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
Fennec Pharmaceuticals Inc. will announce its first quarter 2026 financial results on May 14, 2026, before U.S. market opening. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company is focused on its product PEDMARK, which has received several regulatory approvals to combat ototoxicity in cancer patients.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES ACCEPTANCE of ABSTRACTS at the 2026 ASCO Annual Meeting
Fennec Pharmaceuticals announced the acceptance of four abstracts related to PEDMARK® at the 2026 ASCO Annual Meeting. These studies focus on the prevention of cisplatin-induced hearing loss in pediatric and young adult cancer patients. PEDMARK® is FDA-approved for reducing ototoxicity associated with cisplatin treatment, highlighting its significance in improving patient outcomes.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES ACCEPTANCE of ABSTRACTS at the 2026 ASCO Annual Meeting - Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Imp
Fennec Pharmaceuticals announced that four abstracts concerning their PEDMARK treatment have been accepted for the 2026 ASCO Annual Meeting. PEDMARK is designed to prevent cisplatin-induced hearing loss among pediatric and young adult cancer patients. The accepted studies highlight the increasing clinical interest in tackling ototoxicity associated with cisplatin chemotherapy. This follows the FDA approval of PEDMARK, which represents a significant advancement in protective treatments for patients undergoing such therapies.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES Investigator-SPONSORED STUDY to be Conducted by University of Arizona Cancer Center
Fennec Pharmaceuticals has announced a new investigator-sponsored study by the University of Arizona Cancer Center to evaluate the efficacy of PEDMARK in AYA and adult patients with solid tumors receiving cisplatin. This study aims to explore the drug's potential in preventing cisplatin-induced ototoxicity. The initiative adds to Fennec's ongoing efforts to expand the use of PEDMARK in various patient populations.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES Investigator-SPONSORED STUDY to be Conducted by University of Arizona Cancer Center ~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK in AYA & Adult Patient
Fennec Pharmaceuticals has announced an investigator-sponsored study by the University of Arizona Cancer Center to evaluate the use of PEDMARK in adolescent and adult patients with solid tumors undergoing cisplatin treatment. This study aims to expand the understanding of PEDMARK's benefits in new patient populations. With previous FDA approval and ongoing independent research, Fennec aims to enhance real-world validation and broader clinical adoption of PEDMARK, which is indicated for reducing the risk of cisplatin-induced ototoxicity.
Read more →FENC▲ +6.6%on this news
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fennec Pharmaceuticals announced the grant of 377,500 incentive stock options to 24 new non-executive employees as part of its 2026 Equity Inducement Plan. The options, priced at $5.77 per share, are intended to attract talent and support the company's growth. Fennec is focused on its product PEDMARK/PEDMARQSI, which has received various regulatory approvals to combat ototoxicity in cancer patients.
Read more →FENC▼ -19.2%on this news
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported strong financial results for Q4 and FY 2025, with net product sales reaching $44.6 million, marking a 50% increase from the previous year. The company achieved record patient enrollments and positive clinical study results for PEDMARK in Japan. Fennec is expanding its clinical data strategy and enhancing its field team to further drive growth.
Read more →FENCFennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
Fennec Pharmaceuticals Inc. has announced the date for its full year and fourth quarter 2025 financial results, set to be revealed on March 24, 2026. The company will host a conference call and webcast on that day to discuss their financial outcomes and future business strategy. Fennec's product, PEDMARK, which targets ototoxicity in cancer patients, continues to gain traction with recent approvals in multiple regions.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION
Fennec Pharmaceuticals has settled litigation with Cipla regarding the latter's attempt to market a generic version of PEDMARK, a sodium thiosulfate injection. The settlement ensures that Cipla will not enter the market until September 1, 2033, allowing Fennec to maintain exclusivity. PEDMARK is the only FDA-approved therapy aimed at reducing cisplatin-induced ototoxicity in pediatric patients.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION Research Triangle Park, NC
Fennec Pharmaceuticals has announced a settlement with Cipla Limited and Cipla USA to resolve ongoing patent litigation concerning the generic version of their drug PEDMARK. The settlement stipulates that Cipla will not introduce a generic version of sodium thiosulfate until September 1, 2033, or earlier under specific conditions. This resolution allows Fennec to retain market exclusivity for its FDA-approved therapy aimed at preventing ototoxicity in pediatric patients undergoing cisplatin chemotherapy. The agreement reflects Fennec's ongoing commitment to this critical area in pediatric oncology.
Read more →FENCFennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
Fennec Pharmaceuticals has partnered with Tampa General Hospital to study the clinical utility of sodium thiosulfate injection (PEDMARK®) in reducing ototoxicity in cancer patients undergoing cisplatin treatment. This initiative aims to gather real-world data to better inform future research and improve patient outcomes. PEDMARK® is already FDA-approved for pediatric patients and has shown efficacy in protecting against hearing loss.
Read more →FENCFennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
Fennec Pharmaceuticals presented new real-world data at the 2026 Multidisciplinary Head and Neck Cancers Symposium, indicating that PEDMARK® can be safely administered to adults with head and neck cancers at least six hours after cisplatin treatment. The findings suggest that PEDMARK® may help preserve hearing without compromising the antitumor efficacy of cisplatin. Most patients in the study experienced no measurable hearing loss, highlighting the drug's potential in addressing a significant survivorship challenge.
Read more →FENCFENNEC PHARMACEUTICALS PRESENTS REAL WORLD DATA SUPPORTING THE integration AND CLINICAL USE OF Pedmark® IN TREATING ADULTS WITH HEAD & nECK CANCERS
Fennec Pharmaceuticals presented new real-world data on PEDMARK® at the 2026 Multidisciplinary Head and Neck Cancers Symposium. The findings indicate that PEDMARK® can be safely administered after cisplatin treatment, preserving its antitumor efficacy while potentially preventing cisplatin-induced hearing loss. Most high-risk patients showed no measurable hearing loss during or after treatment.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES Investigator-SPONSORED TRIAL to be Conducted by CITY OF HOPE IN Metastatic Testicular Germ Cell Tumors
Fennec Pharmaceuticals announced an investigator-sponsored trial by City of Hope to evaluate PEDMARK for reducing cisplatin-induced ototoxicity in adult men with metastatic testicular germ cell tumors. The study aims to address the significant hearing loss experienced by survivors of cisplatin chemotherapy. This reflects a growing interest in improving quality of life for cancer patients through comprehensive care.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES Investigator-SPONSORED TRIAL to be Conducted by CITY OF HOPE IN Metastatic Testicular Germ Cell Tumors - City of Hope to Evaluate PEDMARK for Reducing Ototoxicity in Adult Men with Stage
Fennec Pharmaceuticals announced the initiation of an investigator-sponsored trial led by City of Hope to evaluate its drug PEDMARK for preventing cisplatin-induced ototoxicity in adult men with metastatic testicular germ cell tumors. This study aims to address the issue of permanent hearing loss experienced by many cancer survivors treated with cisplatin-based chemotherapy. The research highlights the need for improved survivorship care that encompasses both treatment effectiveness and quality of life. PEDMARK is already FDA approved for pediatric patients and is recognized for its potential benefits in the adolescent and young adult populations as well.
Read more →FENCFennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
Fennec Pharmaceuticals announced positive topline results from the Phase 2/3 STS-J01 clinical trial of PEDMARK in Japan. The study demonstrated a significant reduction in cisplatin-induced hearing loss among pediatric patients, with rates of 24% and 16% compared to historical rates of 56-63%. Additionally, PEDMARK did not interfere with cisplatin's antitumor efficacy, showing a 95% clinical response rate. The company plans to pursue registration and explore licensing opportunities in Japan.
Read more →FENCFENNEC PHARMACEUTICALS TO PARTICIPATE IN PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE
Fennec Pharmaceuticals Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. The event will feature a fireside chat available via webcast. Fennec is focused on its product, PEDMARK, which aims to reduce ototoxicity in cancer patients undergoing chemotherapy. The company has secured various regulatory approvals for PEDMARK and is expanding its commercialization efforts.
Read more →FENCFennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Fennec Pharmaceuticals will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. The event will feature a fireside chat available via webcast. Fennec is focused on its product PEDMARK, which aims to reduce ototoxicity in cancer patients undergoing cisplatin-based chemotherapy. The product has received FDA and European approvals, enhancing its market presence.
Read more →FENC▼ -6.5%on this news
FENNEC PHARMACEUTICALS ANNOUNCES FULL DEBT REDEMPTION Research Triangle Park, NC
Fennec Pharmaceuticals has announced the full redemption of its outstanding convertible notes, totaling over $21.7 million, financed through proceeds from a recent public offering and private placement. Following this action, the company has eliminated all of its debt, which is expected to strengthen its financial position. Fennec's lead product, PEDMARK, is available in multiple markets after receiving necessary approvals, with a strategic licensing agreement in place for broader commercialization efforts. This positive liquidity event reflects Fennec's commitment to its operations amid ongoing product launches.
Read more →FENC▼ -6.5%on this news
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
Fennec Pharmaceuticals Inc. has announced the successful completion of the redemption of all its outstanding convertible notes, amounting to approximately $21.7 million, funded by proceeds from its recent public offering. This move leaves the company without any outstanding debt, positioning it strongly for future growth. Fennec is focused on commercializing its product PEDMARK®, which has received significant regulatory approvals for use in reducing the risk of ototoxicity in cancer patients undergoing chemotherapy.
Read more →FENC▼ -6.5%on this newsshared move
FENNEC PHARMACEUTICALS ANNOUNCES CLOSING OF OFFERING OF COMMON SHARES
Fennec Pharmaceuticals has successfully closed its public offering of 5,366,667 common shares at $7.50 per share, raising approximately $40.25 million. The proceeds will be used to repay certain debts and for general corporate purposes. The offering was managed by Piper Sandler & Co. and Craig-Hallum Capital Group LLC. Fennec continues to focus on its product PEDMARK®, which has received various regulatory approvals.
Read more →FENCFennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada
Fennec Pharmaceuticals has announced the successful closing of a private offering of its common shares in Canada, generating gross proceeds of approximately $5.03 million at $7.50 per share. The offering was conducted under a financing exemption that allows it to attract institutional investors without a hold period on the shares. Fennec continues to focus on its specialized product, PEDMARK®, which aims to reduce ototoxicity in cancer patients, and has received several regulatory approvals across different regions.
Read more →FENC▲ +11.3%on this newsshared move
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
Fennec Pharmaceuticals Inc. has announced the successful closing of its underwritten public offering of 5,366,667 common shares at a price of $7.50 per share. The total gross proceeds from this offering amount to approximately $40.25 million. Fennec plans to utilize the net proceeds primarily for repaying certain debts and for general corporate purposes. The offering was managed by several financial institutions, and the details are fully disclosed in the SEC filings.
Read more →FENC▲ +11.3%on this newsshared move
FENNEC PHARMACEUTICALS ANNOUNCES PRIVATE OFFERING OF COMMON SHARES IN CANADA
Fennec Pharmaceuticals Inc. announced a non-brokered offering of common shares in Canada, aiming to raise up to $5,025,000 at $7.50 per share. The offering is set to close on November 17, 2025, pending subscription agreements and regulatory approvals. The shares will be offered under a financing exemption, with no hold period under Canadian securities laws.
Read more →FENC▲ +11.3%on this newsshared move
FENNEC PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Fennec Pharmaceuticals reported its third quarter 2025 financial results, achieving record net product sales of $12.5 million, marking a 79% increase compared to the same quarter in 2024. The company also experienced its first profitable quarter from operations and positive cash flow. The adoption of PEDMARK® continues to grow, particularly within key oncology networks, while preliminary results from a clinical trial in Japan are anticipated in Q4 2025.
Read more →FENC▲ +11.3%on this newsshared move
FENNEC PHARMACEUTICALS ANNOUNCES PROPOSED OFFERING OF COMMON SHARES
Fennec Pharmaceuticals Inc. has announced a proposed public offering of its common shares, with plans to use the proceeds for debt reduction and general corporate purposes. The offering includes an option for underwriters to purchase additional shares. The company is focused on its product PEDMARK®, which has received various regulatory approvals.
Read more →FENCFennec Pharmaceuticals Announces Pricing of Offering of Common Shares
Fennec Pharmaceuticals announced the pricing of its public offering of 4,666,667 common shares at $7.50 each, aiming to raise about $35 million. The offering will close on November 17, 2025, subject to customary conditions. Fennec plans to use the proceeds to repurchase certain debts and for general corporate purposes. Alongside this, the company continues to expand its market with the recent licensing agreement for its product PEDMARQSI® in Europe and other regions.
Read more →FENCFennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported a strong Q3 2025 financial performance, with net product sales reaching $12.5 million, a significant 79% increase compared to the previous year. The company achieved its first profitable quarter from operations and positive cash flow, highlighting its successful restructuring strategy. Fennec expects preliminary results from a clinical trial in Japan by the end of 2025, which could enhance its market presence. Overall, the company is well-positioned for sustained growth, particularly with the increasing adoption of its product PEDMARK® among healthcare providers.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES PROPOSED OFFERING OF COMMON SHARES Research Triangle Park, NC
Fennec Pharmaceuticals Inc. has announced a proposed offering of its common shares in a registered public offering. The company plans to utilize the net proceeds to repurchase certain debts and for working capital. In addition, Fennec is granting underwriters a 30-day option to purchase up to an additional 15% of shares sold. This move comes after the successful launch of its drug PEDMARK in the U.S. and PEDMARQSI in Europe, aimed at reducing ototoxicity in cancer patients.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES PRIVATE OFFERING OF COMMON SHARES IN CANADA Research Triangle Park, NC
Fennec Pharmaceuticals has announced a private non-brokered offering of common shares in Canada, aiming to raise up to $5,025,000 at a price of $7.50 per share. The offering is anticipated to close on November 17, 2025, subject to customary conditions and approvals from the Toronto Stock Exchange. The shares will be available to prospective buyers in Canadian provinces, excluding Quebec, under the listed issuer financing exemption. While the offering could enhance the company's financial standing, there are risks associated with its successful completion and the overall business environment.
Read more →FENCFENNEC PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Fennec Pharmaceuticals reported a strong financial performance for Q2 2025, with net revenues of $9.7 million, reflecting a 33% increase compared to the previous year. The company highlighted successful growth in large community practices and academic centers, driven by an enhanced sales strategy and patient support services for its product, PEDMARK. Additionally, the initial uptake of PEDMARQSI in Europe shows promising market potential, with further launches planned.
Read more →FENC▼ -6.4%on this newsshared move
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
Fennec Pharmaceuticals reported a 33% increase in total net revenues for Q2 2025, reaching $9.7 million. The company highlighted strong growth in new accounts, particularly in large community practices and academic centers. Additionally, initial uptake of its product PEDMARQSI in Europe is promising, with further launches planned. Results from a clinical trial in Japan are expected later this year.
Read more →FENCFennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
Fennec Pharmaceuticals Inc. will announce its financial results for the second quarter of 2025 on August 14, 2025. This release will occur before U.S. markets open, and the company plans a conference call for stakeholders to discuss these results. Fennec is known for its product PEDMARK, which protects cancer patients from cisplatin-induced hearing loss. The company has successfully gained regulatory approvals for PEDMARK/PEDMARQSI in various regions and established a licensing agreement to enhance its market presence.
Read more →FENCFennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported its financial results for the first quarter of 2025, showcasing an 18% increase in total net revenues compared to the same period last year, reaching approximately $8.8 million. The company highlighted the commercial launch of PEDMARQSI in Germany and the UK and improvements in its patient support program, Fennec HEARS™, as key business developments. Despite these gains, the company incurred a net loss of $1.165 million, and general administrative expenses saw an increase due to stock-based compensation.
Read more →FENCFennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Fennec Pharmaceuticals Inc. will announce its first quarter 2025 financial results on May 13, 2025, before U.S. market opening. Management plans to host a conference call and webcast for discussion of financial and business outcomes. The company is known for its development of PEDMARK, which has received regulatory approvals in the U.S., Europe, and the U.K. for reducing platinum-induced ototoxicity in pediatric patients. The financial call reflects the ongoing engagement with investors and the market.
Read more →FENC▲ +5.3%on this news
FENNEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Fennec Pharmaceuticals reported a strong financial performance for Q4 and full-year 2024, with PEDMARK sales reaching $29.6 million, a 40% increase from the previous year. The company also launched PEDMARQSI in the UK and Germany, expanding access to its treatment for cisplatin-induced ototoxicity. Despite a slight EBITDA loss, Fennec's strategic investments and leadership enhancements position it for growth in 2025.
Read more →FENC▼ -11.2%on this newsshared move
FENNEC PHARMACEUTICALS TO REPORT FULL YEAR AND FOURTH QUARTER 2024 FINANCIAL RESULTS ON MARCH 10, 2025
Fennec Pharmaceuticals Inc. will announce its full year and fourth quarter 2024 financial results on March 10, 2025, before U.S. market opening. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results. Fennec is known for its product PEDMARK, which has received several regulatory approvals.
Read more →FENC▼ -11.2%on this newsshared move
FENNEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved Full-Year PEDMARK Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMAR
Fennec Pharmaceuticals reported strong financial results for the fourth quarter and full year of 2024, with a significant 40% increase in PEDMARK net product sales, totaling $29.6 million. The company improved its financial stability by repaying $13 million of its convertible debt, enhancing its capital structure. Additionally, Fennec is witnessing positive momentum in the adoption of PEDMARK in academic settings following strategic investments. The company's PEDMARQSI product is now commercially available in the UK and Germany, with further clinical trial results anticipated in 2025.
Read more →FENCFennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
Fennec Pharmaceuticals Inc. is set to announce its full year and fourth quarter 2024 financial results on March 10, 2025. The company will hold a conference call and webcast to discuss these results before the U.S. financial markets open. The event emphasizes the company's commitment to transparency with its investors and stakeholders, providing a platform for discussion on financial and business performance.
Read more →FENCFennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
Fennec Pharmaceuticals has announced the commercial launch of PEDMARQSI in Germany, the first therapy approved in the EU and U.K. to prevent hearing loss caused by cisplatin chemotherapy in children. This launch is part of a broader strategy to increase access to the drug across Europe. The therapy has shown a 50% reduction in cisplatin-induced ototoxicity in clinical trials.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES PEDMARQSI Ò POSITIVE RECOMMENDATION BY NICE FOR THE PREVENTION OF CISPLATIN-INDUCED HEARING LOSS IN ENGLAND AND WALES ~ PEDMARQSI (anhydrous sodium thiosulfate) is the first and on
Fennec Pharmaceuticals has announced that its treatment PEDMARQSI has received a positive recommendation from NICE for preventing cisplatin-induced hearing loss in children and young adults in England and Wales. PEDMARQSI, which is the first approved therapy for this indication, showed about a 50% reduction in hearing loss risk in two significant Phase 3 trials. The approval addresses a previously unmet need in pediatric oncology, and the company has also secured a lucrative licensing deal with Norgine Pharmaceuticals for commercialization. This development marks a critical milestone for both Fennec and the cancer community in managing treatment-related hearing loss in younger patients.
Read more →FENCFennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
Fennec Pharmaceuticals announced that NICE has issued positive guidance for PEDMARQSI, the first therapy to prevent cisplatin-induced hearing loss in pediatric patients aged 1 month to 17 years. This approval highlights a significant step forward in addressing an unmet need in pediatric oncology, as cisplatin treatments can lead to permanent hearing loss in survivors. The favorable recommendation is expected to enhance the drug's accessibility and impact on patient care. Fennec's partnership with Norgine further strengthens its market presence in Europe and other regions.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES EARLY PARTIAL REPAYMENT OF ITS OUTSTANDING CONVERTIBLE DEBT FACILITY WITH PETRICHOR HEALTHCARE CAPITAL MANAGEMENT
Fennec Pharmaceuticals has announced the early repayment of $13 million of its convertible debt to Petrichor Healthcare Capital Management. This repayment will reduce the outstanding debt to approximately $19 million and save the company about $1.5 million in annual interest expenses. The move is part of Fennec's strategy to optimize its balance sheet and support its growth plans for PEDMARK.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES EARLY PARTIAL REPAYMENT OF ITS OUTSTANDING CONVERTIBLE DEBT FACILITY WITH PETRICHOR HEALTHCARE CAPITAL MANAGEMENT ~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Eliminat
Fennec Pharmaceuticals has announced an early partial repayment of $13 million towards its outstanding convertible debt facility with Petrichor Healthcare Capital Management. This strategic move reduces its debt to approximately $19 million and will save the company about $1.5 million in annual interest expenses. The repayment was funded entirely with available cash, indicating financial stability and a strong capital structure. Looking ahead, the company expects that its cash and investments will support operations into 2026.
Read more →FENCFennec Pharmaceuticals to Participate in Upcoming Investor Conference
Fennec Pharmaceuticals announced its participation in the virtual H.C. Wainwright @ Home Fireside Chat Series on December 16, 2024. This involvement highlights the company's ongoing efforts to engage with investors. Fennec has achieved significant regulatory milestones with its product, PEDMARK, aimed at preventing platinum-induced ototoxicity in children. The company has secured approvals from the FDA, European Commission, and U.K. for its products.
Read more →FENCFENNEC PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCE
Fennec Pharmaceuticals Inc. will participate in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024. The event will take place at the Sheraton New York Times Square Hotel, where the company's management will hold one-on-one meetings with investors. Fennec focuses on reducing platinum-induced ototoxicity in pediatric patients with its product PEDMARK, which has received several regulatory approvals.
Read more →FENC▼ -11.9%on this news
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported its financial results for Q3 2024, noting net product sales of $7 million, representing growth from the previous year. The company successfully achieved over 90% reimbursement for its drug PEDMARK in the adolescent and young adult market. Fennec has strengthened its leadership team with new executive appointments and maintains a strong cash reserve expected to fund operations into at least 2026. However, the company also reported an increased net loss compared to the same period last year, alongside rising operational expenses.
Read more →FENCFennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Fennec Pharmaceuticals Inc. has announced the release date for its third quarter 2024 financial results, scheduled for November 7, 2024, prior to the opening of the U.S. financial markets. The company will hold a conference call and webcast that morning to discuss its financial performance. Fennec is known for its specialty pharmaceutical focus, particularly regarding PEDMARK, a drug aimed at preventing platinum-induced ototoxicity in pediatric patients, which has seen recent approvals in various regions.
Read more →FENC▲ +11.6%on this newsshared move
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth
Fennec Pharmaceuticals has announced the appointment of three key executives to enhance its leadership team. Pierre S. Sayad becomes Chief Medical Officer, Terry Evans is appointed Chief Commercial Officer, and Christiana Cioffi takes on the role of Chief Strategy Officer. These appointments aim to accelerate the company's growth and improve its commercialization strategy for PEDMARK, the first therapy approved to reduce ototoxicity risk in pediatric patients undergoing cisplatin treatment.
Read more →FENC▲ +11.6%on this newsshared move
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth ~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appo
Fennec Pharmaceuticals has announced the strengthening of its executive leadership team with three key appointments: Pierre S. Sayad as Chief Medical Officer, Terry Evans as Chief Commercial Officer, and Christiana Cioffi as Chief Strategy Officer. These appointments aim to accelerate the company's growth and enhance its commercialization strategy, particularly for its innovative therapy, PEDMARK. PEDMARK is the only FDA-approved treatment designed to prevent hearing loss related to cisplatin treatment in pediatric patients, a significant advancement in oncology care. The new executives bring substantial industry experience and expertise to the company as it seeks to make a meaningful difference in the lives of young cancer patients.
Read more →FENCFENNEC PHAMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
Fennec Pharmaceuticals Inc. will participate in two upcoming investor conferences in September 2024. The management team will host presentations and one-on-one meetings at these events. The company focuses on its FDA-approved product, PEDMARK, which aims to reduce platinum-induced ototoxicity in pediatric patients.
Read more →FENCFennec Pharmaceuticals to Participate in Upcoming Investor Conferences
Fennec Pharmaceuticals announced its participation in two upcoming investor conferences, aiming to enhance engagement with investors. The company will present at the H.C. Wainwright Global Investment Conference on September 11, 2024, and at the Cantor Fitzgerald Global Healthcare Conference on September 19, 2024. Additionally, one-on-one investor meetings will be hosted by the management team during these events to bolster investor relations. Fennec is known for its specialty drug, PEDMARK, designed to mitigate platinum-induced ototoxicity in pediatric patients.
Read more →FENC▼ -6.4%on this news
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported its second quarter 2024 financial results, achieving total net revenues of $7.3 million, an increase from $3.3 million in Q2 2023. The company appointed Jeff Hackman as its new CEO, who aims to enhance outreach to community oncology and the adolescent and young adult (AYA) populations. Despite a net loss of $5.6 million, Fennec maintains a robust cash position of approximately $43 million. The company also participated in significant scientific meetings, enhancing its commitment to oncology care.
Read more →FENCFennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
Fennec Pharmaceuticals Inc. plans to release its financial results for the second quarter of 2024 before the U.S. markets open on August 13, 2024. A conference call and webcast will follow to discuss these results. Additionally, the company will participate in the 2024 Wedbush PacGrow Healthcare Conference in New York, allowing further interaction with investors. Fennec specializes in treatments to mitigate platinum-induced ototoxicity in pediatric patients, with promising drug approvals in recent years.
Read more →FENCFENNEC PHARMACEUTICALS APPOINTS JEFFREY S. HACKMAN AS CHIEF EXECUTIVE OFFICER AND DIRECTOR
Fennec Pharmaceuticals has appointed Jeffrey S. Hackman as CEO, effective August 16, 2024. Hackman brings over 30 years of experience in commercialization, particularly in oncology. His leadership comes at a crucial time as Fennec aims to expand the use of PEDMARK®, the first approved treatment for reducing the risk of cisplatin-induced ototoxicity in pediatric patients. Former CEO Rosty Raykov will remain on the Board of Directors.
Read more →FENCFennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director ~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical
Fennec Pharmaceuticals has appointed Jeffrey S. Hackman as the new Chief Executive Officer and Director, effective August 16, 2024. Hackman brings extensive experience in commercialization, particularly in oncology, which is expected to aid in the expansion of PEDMARK, the company's leading treatment for reducing the risk of cisplatin-induced ototoxicity in pediatric cancer patients. This leadership change is seen as timely for the company's strategic direction towards operational success in the oncology community.
Read more →FENCFennec Pharmaceuticals Announces Management Change
Fennec Pharmaceuticals announced the departure of Chief Operating Officer Adrian Haigh as of June 30, 2024, after a brief tenure in the role. CEO Rosty Raykov acknowledged Haigh's contributions to the company, particularly during its licensing agreement with Norgine for PEDMARQSI. Following a strategic refocusing towards treating the community treated AYA population, Fennec is now in search of a new U.S.-based leader with expertise in commercializing oncology products. This transition marks a critical point for Fennec as it navigates its growth in a competitive market.
Read more →FENC▼ -26.7%on this news
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported significant financial results for the first quarter of 2024, achieving total net revenues of $25.4 million, boosted by an $18 million licensing agreement with Norgine. The company also amended its PEDMARK J-code to specify its differentiation from other sodium thiosulfate formulations. Additionally, Fennec's cash position improved to approximately $51 million, ensuring sufficient funding for its operations in the upcoming year. The company is focusing on expanding PEDMARK use in the outpatient oncology community following NCCN recommendations for the AYA population.
Read more →FENCFennec Pharmaceuticals to Report First Quarter 2024 Financial Results on
Fennec Pharmaceuticals Inc. has announced that it will report its first quarter 2024 financial results on May 14, 2024, prior to the opening of the U.S. financial markets. The company will hold a conference call and webcast on the same day to discuss these results. Fennec specializes in developing treatments for pediatric patients, particularly focusing on its FDA-approved products PEDMARK and PEDMARQSI, which address platinum-induced ototoxicity. Both products have received significant regulatory approvals, enhancing the company's market presence.
Read more →FENCFENNEC PHARMACEUTICALS TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 14, 2024
Fennec Pharmaceuticals Inc. announced it will release its first quarter 2024 financial results on May 14, 2024, before U.S. markets open. A conference call and webcast will follow at 8:30 a.m. ET to discuss these results. The company continues to focus on its products aimed at pediatric patients, with recent approvals for PEDMARK and PEDMARQSI.
Read more →FENCFennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
Fennec Pharmaceuticals Inc. is set to release its first quarter 2024 financial results before the U.S. markets open on May 14, 2024. The company will also host a conference call and webcast to discuss its financial and business performance. Fennec focuses on reducing platinum-induced ototoxicity in pediatric patients, with its products receiving significant regulatory approvals.
Read more →FENCFENNEC PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Fennec Pharmaceuticals reported strong financial results for 2023, achieving net product sales of $21.3 million, driven by the success of PEDMARK. The company entered a licensing agreement with Norgine for PEDMARQSI, enhancing its financial outlook. Despite a net loss of $16 million, Fennec maintains a robust cash position, setting the stage for growth in 2024.
Read more →FENCFENNEC PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved PEDMARK Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product
Fennec Pharmaceuticals announced its financial results for the fiscal year 2023, highlighting net product sales of $21.3 million from its PEDMARK therapy. The company has also secured an exclusive licensing agreement for its PEDMARQSI product to be commercialized in Europe, Australia, and New Zealand, potentially worth up to $273 million. Despite these positive developments, Fennec reported a substantial net loss and high accumulated liabilities, raising concerns about its financial stability moving forward.
Read more →FENCFENNEC PHARMACEUTICALS AND NORGINE ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE PEDMARQSI IN EUROPE, AUSTRALIA, AND NEW ZEALAND
Fennec Pharmaceuticals has entered an exclusive licensing agreement with Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand. The agreement includes an upfront payment of €40 million and potential additional payments of up to €210 million. PEDMARQSI is the first approved therapy for preventing cisplatin-induced hearing loss in pediatric patients. Norgine will manage all commercialization activities in the licensed territories.
Read more →FENCFENNEC PHARMACEUTICALS REPORTS PRELIMINARY UNAUDITED NET REVENUE FOR FOURTH QUARTER AND FULL-YEAR 2023 RESULTS
Fennec Pharmaceuticals reported preliminary unaudited net revenues for Q4 and full-year 2023, estimating revenues of approximately $9.2 to $9.7 million for Q4, reflecting a 41-49% increase from Q3. The company is set to release audited results on or about March 26, 2024. PEDMARK, its FDA-approved therapy, aims to reduce ototoxicity in pediatric patients undergoing chemotherapy.
Read more →FENCFennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
Fennec Pharmaceuticals Inc. is set to release its full year and fourth quarter 2023 financial results on March 21, 2024, prior to the market opening. The company will hold a conference call and webcast to discuss the financial and business results for investors. Fennec, known for its focus on pediatric treatments, recently received several regulatory approvals for its products aimed at reducing platinum-induced ototoxicity. This move demonstrates continued activity and transparency from the company in a competitive sector.
Read more →FENC▲ +11.4%on this newsshared move
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand Agreement pairs Norgine's commercial expertise and leading European footprint w
Fennec Pharmaceuticals has entered into an exclusive licensing agreement with Norgine to commercialize its product PEDMARQSI in Europe, Australia, and New Zealand. The therapy, approved for reducing cisplatin-induced hearing loss in pediatric cancer patients, is the first of its kind in the EU and U.K. Fennec will receive $40 million upfront and up to $210 million in milestone payments, with Norgine taking charge of all marketing efforts. The collaboration aims to provide essential treatment for over 5,000 eligible pediatric patients annually in the specified regions.
Read more →FENCPharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
Fennec Pharmaceuticals Inc. has announced its preliminary unaudited net revenues for the fourth quarter and full year of 2023, projecting revenues between $9.2 and $9.7 million. The company plans to release the audited financial results around March 26, 2024. PEDMARK, the company's FDA-approved therapy, is highlighted for its unique ability to reduce the risk of ototoxicity in pediatric cancer patients receiving cisplatin treatment.
Read more →FENCFennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results ~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 F
Fennec Pharmaceuticals has reported preliminary unaudited net revenues for the fourth quarter and full-year results of 2023, estimating revenues between $9.2 million and $9.7 million. The company plans to release its audited full-year results on March 26, 2024. PEDMARK, their primary product, is FDA approved for reducing the risk of ototoxicity in pediatric cancer patients undergoing platinum-based therapies. The company has also achieved Orphan Drug Exclusivity for PEDMARK in the U.S. and has a commercial strategy in place for its offerings in both the U.S. and Europe.
Read more →FENCFDA Issues Reminder of Non-Substitution of PEDMARK Ò (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
Fennec Pharmaceuticals Inc. announced that the FDA has issued a reminder to healthcare providers regarding PEDMARK, a sodium thiosulfate injection. The FDA clarified that PEDMARK is not interchangeable with other sodium thiosulfate products, emphasizing its importance in reducing the risk of hearing loss in pediatric patients undergoing cisplatin therapy. The reminder aims to ensure patient safety and proper adherence to the prescribing information. PEDMARK received FDA approval in September 2022, highlighting its critical role in pediatric oncological care.
Read more →FENCFENNEC ANNOUNCES INCREMENTAL $5 MILLION INVESTMENT FROM PETRICHOR ~ Supports Strategic Discussions and Global Launch Activities ~ ~ Extends Access to Additional Undrawn Capital As Needed During Global PEDMARK Rollout ~ ~
Fennec Pharmaceuticals announced a $5 million increase in investment from Petrichor, aimed at bolstering strategic discussions and supporting the global rollout of its therapy PEDMARK. The investment extends access to a total of $15 million until December 2024, which Fennec will utilize to expand its market presence in the adolescent and young adult cancer patient population. CEO Rosty Raykov expressed optimism about the early feedback from providers and families regarding PEDMARK, highlighting its unique role in preventing hearing loss in pediatric patients undergoing chemotherapy.
Read more →FENC▲ +15.4%on this newsshared move
FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ PEDMARK Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Und
Fennec Pharmaceuticals Inc. has reported strong financial results for the third quarter ended September 30, 2023, showcasing a significant increase in net product revenue from PEDMARK, totaling $6.5 million and up by 96% from the previous quarter. Management highlighted strong commercial uptake and expressed confidence in expanding the prescriber base to further enhance utilization of their products. Additionally, the company received regulatory approval for PEDMARQSI in the U.K., which is expected to bolster their market presence in Europe. Despite these positive developments, Fennec experienced a net loss and a growing deficit, raising concerns about their financial stability moving forward.
Read more →FENCFennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023
Fennec Pharmaceuticals Inc. announced it will release its third quarter 2023 financial results on November 6, 2023, before the U.S. financial markets open. A conference call and webcast will follow at 8:30 a.m. Eastern Time to discuss the financial and business outcomes. The company focuses on developing products to prevent platinum-induced ototoxicity in pediatric patients and has recently gained various regulatory approvals for its therapies.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER
Fennec Pharmaceuticals reported its financial results for the second quarter ended June 30, 2023, showcasing a remarkable 98% revenue increase to $3.3 million, primarily driven by the commercial launch of its drug PEDMARK. The company announced the appointment of Adrian Haigh as Chief Operating Officer, enhancing its leadership team with his extensive industry experience. Management will discuss the financial results and outlook for the remainder of 2023 in an upcoming conference call.
Read more →FENC▼ -7.3%on this newsshared move
FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Growing Physician Awareness and Usage of PEDMARK Drove Quarterly Revenue Growth of 98% ~ ~Fennec Expands Leadership Te
Fennec Pharmaceuticals released its financial results for Q2 2023, highlighting a 98% increase in net revenue attributed to enhanced physician awareness of its product, PEDMARK. The company has appointed Adrian Haigh as Chief Operating Officer to strengthen its leadership team. While the results reflect strong growth, the company also reported an increasing net loss and high operating expenses, signaling ongoing financial challenges despite the positive revenue trend. A conference call is scheduled to provide further insights into the financial performance and business outlook.
Read more →FENC▲ +8.7%on this newsshared move
Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023
Fennec Pharmaceuticals Inc. has announced that it will publish its second quarter 2023 financial results on August 3, 2023, ahead of the U.S. market opening. The company will conduct a conference call and webcast that morning to discuss the results. Fennec specializes in developing treatments to mitigate platinum-induced ototoxicity in pediatric patients and has recently received various approvals for its product PEDMARK and its counterpart Pedmarqsi. Stakeholders are encouraged to register for the conference call to participate in the discussion.
Read more →FENCFennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients ~ Pedmarqsi is the First and Only Approved
Fennec Pharmaceuticals has received marketing authorization from the European Commission for Pedmarqsi, the first therapy available in the EU to prevent cisplatin-induced hearing loss in pediatric oncology patients. The approval follows positive results from two Phase 3 trials and includes 10 years of market protection. The therapy will aid around 4,000 children treated with cisplatin annually by addressing a common and severe side effect. This marks a significant advancement for treating localized, non-metastatic solid tumors in pediatric patients.
Read more →FENCFennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported its financial results for Q1 2023, showcasing strong commercial momentum for PEDMARK® and positive developments including a permanent reimbursement J-Code. The company received a favorable opinion from the EMA's CHMP for PEDMARQSI™, indicating important progress in addressing cisplatin-induced hearing loss in pediatric patients. However, financial results also revealed an increase in net loss compared to the previous year, and a decline in cash reserves from the end of 2022, raising questions about future funding. Overall, the company continues to make strides in expanding its product offerings and gaining market acceptance.
Read more →FENCFennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
Fennec Pharmaceuticals Inc. will announce its first quarter 2023 financial results on May 11, 2023, before U.S. market openings. The announcement comes with a scheduled conference call and webcast for management to discuss the company's performance. The company focuses on the development of PEDMARK®, an FDA-approved drug to prevent platinum-induced ototoxicity in pediatric patients. Fennec also holds exclusive worldwide licensing rights for related intellectual properties.
Read more →FENCFennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients ~ First Therapy Recommended for Approval in the European Union fo
Fennec Pharmaceuticals has received a positive opinion from the CHMP for Pedmarqsi (sodium thiosulfate), aimed at preventing cisplatin-induced hearing loss in pediatric patients aged 1 month to under 18 years. This treatment is poised to be the first approved therapy in the EU for such complications, based on strong clinical data showing a significantly lower incidence of hearing loss compared to chemotherapy alone. The recommendation is based on two pivotal Phase 3 trials, which demonstrated a favorable benefit-risk profile for Pedmarqsi. The final approval by the European Commission is anticipated by early June 2023.
Read more →FENCFennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results
Fennec Pharmaceuticals reported its financial results for 2022 and shared updates regarding its FDA-approved product, PEDMARK®. The commercial launch of PEDMARK®, launched in October 2022, is demonstrating initial success with recorded net product sales of $1.54 million. The company has sufficient cash resources to support its planned commercial activities for 2023. In addition, Fennec received Orphan Drug Exclusivity for PEDMARK®, which may aid its market presence going forward.
Read more →FENC▲ +6.3%on this news
Fennec Pharmaceuticals Announces PEDMARK (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA ~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Asso
Fennec Pharmaceuticals announced that the FDA granted Orphan Drug Exclusivity to PEDMARK, a sodium thiosulfate injection, the first FDA-approved treatment to reduce ototoxicity risks in pediatric patients undergoing cisplatin therapy. This exclusivity provides seven years of market protection, enhancing PEDMARK's potential revenue. The drug is targeted at pediatric patients with localized, non-metastatic solid tumors and is backed by three FDA patents that extend its market reach until 2039. However, the safety of PEDMARK in specific situations remains unclear and requires vigilant monitoring for adverse reactions.
Read more →FENC▲ +8.3%on this news
Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~ PEDMARK is the Firs
Fennec Pharmaceuticals announced the inclusion of PEDMARK (sodium thiosulfate injection) in the updated NCCN Clinical Practice Guidelines to mitigate the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors. PEDMARK is the first FDA-approved treatment for this indication and aims to alleviate the major side effects of cisplatin chemotherapy, which can cause permanent hearing loss in up to 90% of treated children. This guideline change highlights the importance of addressing the impact of hearing loss on children's development and supports the safe management of young cancer patients undergoing chemotherapy.
Read more →FENCFennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update
~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~ ~ Initiated U.S. Commercial Launch of PEDMARK® in October 2022
Read more →FENCFennec Pharmaceuticals Announces Commercial Availability of PEDMARK (sodium thiosulfate injection) in the United States ~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induc
Pharmaceuticals Announces Commercial Availability of PEDMARK (sodium thiosulfate injection) in the ~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~ ~ Fennec HEARS Program Offers Comprehe
Read more →FENC▼ -8.3%on this news
FENNEC PHARMACEUTICALS ANNOUNCES SECOND CLOSING OF $20 MILLION INVESTMENT FROM PETRICHOR ~Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred o
FENNEC PHARMACEUTICALS ANNOUNCES SECOND CLOSING OF $20 MILLION INVESTMENT ~Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMA
Read more →FENC▲ +11.9%on this newsshared move
Fennec Pharmaceuticals Announces FDA Approval of PEDMARK (Sodium Thiosulfate Injection) ~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediat
Fennec Pharmaceuticals Announces FDA Approval of PEDMARK (Sodium Thiosulfate Injection) PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~
Read more →FENCFENNEC PHARMACEUTICALS CLOSES FIRST $5 MILLION INVESTMENT FROM PETRICHOR ~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval
FENNEC PHARMACEUTICALS CLOSES FIRST $5 MILLION INVESTMENT ~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access an Additional $20 Mil
Read more →FENCFennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update
~ PEDMARKTM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ Commercial Team Built Out In Anticipation of U.S. Launch of PEDMARKTM ~ ~ Recently Announced Up to $45 Million in Funding from Petrichor to Support the Potential U.S. Comme
Read more →FENCFennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor ~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Appro
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor ~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access an
Read more →FENCFennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $18.3 Million in Cash a
Read more →FENC▼ -9.3%on this news
Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™
RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug
Read more →FENCFennec Pharmaceuticals, Inc. Investors: Reach out to the Portnoy Law Firm prior to the April 11, 2022 Deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 08, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) investors that a class action lawsuit has
Read more →FENCFennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference
RESEARCH TRIANGLE PARK, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced oto
Read more →FENC▼ -6.4%on this newsshared move
FENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINSTRATION FOR PEDMARK TM Research Triangle Park, NC
FENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINSTRATION FOR PEDMARKTM Triangle Park, NC, March 24, 2022 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug
Read more →FENCFennec Pharmaceuticals Announces Fiscal Year 2021 Financial Results And Provides Business Update
~ Resubmission of NDA for PEDMARK™ Targeted for the First Quarter of 2022 ~ ~ Company has Approximately $21.1 Million in Cash and $5 Million of Funded Debt ~ RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a s
Read more →FENCFENNEC PHARMACEUTICALS INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Fennec Pharmaceuticals Inc. in the United States District Court for the Middle District of North Carolina
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) filed in the United States District Court f
Read more →FENC▲ +5.2%on this news
FENNEC PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE Research Triangle Park, NC
FENNEC PHARMACEUTICALS ANNOUNCES MANAGEMENT Research Triangle Park, NC, Jan. 31, 2022 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the preventi
Read more →FENC▼ -8.2%on this news· ran to -19% by day 1
Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid
Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors TRIANGLE PARK, N.C., November 30, 2021 - Fennec Ph
Read more →FENC▼ -50.4%on this newsshared move
Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastat
Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors ~ FDA Pre-Approval Inspection Identifie
Read more →FENCFennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ If Approved by the FDA, PEDMARK™ Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $24 Million in Cash and C
Read more →FENCFennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ If Approved by the FDA, PEDMARK™ Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $27 Million in Cash and C
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY Research Triangle Park, NC
PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY Triangle Park, NC, June 24, 2021 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thios
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION RESUBMISSION FOR PEDMARK TM ~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for
FENNEC PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION RESUBMISSION FOR PEDMARKTM ~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ NDA Resubmission for PEDMARK for the Prevention of Cisplatin-Induced Ototoxicity for P
Read more →FENCFENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARK TM ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing L
FENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARKTM ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ Research Triangle Park, NC, May 28, 202
Read more →FENCFennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK™ to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~ ~ Company Has Approximately $27 Million in Cash and No Outstanding Debt ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2021
Read more →FENCFennec Announces Fiscal Year 2020 Financial Results and Provides Business Update
~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™ ~ ~ Resubmission of the NDA for PEDMARKTM is Planned for the Second Quarter of 2021 ~ ~ Company Has Approximately $30 Million in Cash
Read more →FENCFennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™ ~ ~ No Clinical Safety or Efficacy Issues Identified; No Additional Studies Required for PEDMARK™ ~ ~ The Company Has Approx
Read more →FENCFENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR PEDMARK TM Research Triangle Park, NC
FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT Research Triangle Park, NC, September 21, 2020 - Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the
Read more →FENCFENNEC PHARMACEUTICALS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Securities Class Action Lawsuit Has Been Filed on Behalf of Shareholders of Fennec Pharmaceuticals, Inc. in the United States District Court for the Middle District of North Carolina
NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”) announces that a federal securities class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina on behalf of investors
Read more →FENCFENNEC ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Fennec Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina on behalf of investors
Read more →FENCFennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~ ~ Strong Financial Position with $38.7 million in cash and no debt ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmace
Read more →FENCFennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update
~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~ ~ Marketing Authorization Application (MAA) Validated by the EMA in February 2020 ~ ~ Strengthened its Financial Position Through a Raise of Approximately $32 Million in Net Proceeds ~ ~ Commercial Readine
Read more →FENCFennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
RESEARCH TRIANGLE PARK, N.C., May 08, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ot
Read more →FENCFennec Announces Closing of Public Offering
RESEARCH TRIANGLE PARK, N.C., May 05, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ot
Read more →FENCFennec Announces Pricing of Public Offering
RESEARCH TRIANGLE PARK, N.C., April 30, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced oto
Read more →FENCFennec Announces Proposed Public Offering of Common Shares Research Triangle Park, N.C.
Fennec Announces Proposed Public Offering Research Triangle Park, N.C., April 29, 2020 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevent
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES FDA FILING ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR PEDMARK TM ~ Potential for PEDMARK to be the First Product for the Prevention of Cisplatin-Induced Hearing Loss in Ch
FENNEC PHARMACEUTICALS ANNOUNCES FDA FILING ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR PEDMARKTM ~ Potential for PEDMARK to be the First Product for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ FDA Grants Priority Review and Sets a Prescri
Read more →FENCFENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR USE OF PEDMARK TM Research Triangle Park, NC
FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR USE OF PEDMARKTM Research Triangle Park, NC, March 5, 2020 - Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfa
Read more →FENCFennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate Potential First Product in Europe for the Prevention of Cisplatin-Induced Hearing Loss i
Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate Potential First Product in Europe for the Prevention of Cisplatin-Induced Hearing Loss in Children Research Triangle Park, NC, Feb. 28, 2020 -
Read more →FENCFENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2019 FINANCIAL RESULTS NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020 Commercial readiness activities in U.S.
FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2019 FINANCIAL NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020 Commercial readiness activities in U.S. underway for potential launch of PEDMARKTM, if approved, in
Read more →FENCFENNEC PHARMACEUTICALS COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION (NDA) TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARK TM AND ALSO SUBMITS MARKETING AUTHORIZATION APPLICATION (MAA) TO EUROPEAN MEDICINES AGENC
PHARMACEUTICALS COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION (NDA) TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARKTM AND ALSO SUBMITS MARKETING AUTHORIZATION APPLICATION (MAA) TO EUROPEAN MEDICINES AGENCY PEDMARKTM1 is Being Developed for Prevention of Cisplatin-Indu
Read more →FENCFENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS NDA (New Drug Application) for PEDMARK TM to be completed in early 2020 Strong financial position with $15.2 million in cash and no debt
FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS Research Triangle Park, NC, November 12, 2019 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formula
Read more →FENCFennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induce
Read more →FENCFENNEC APPOINTS JODI A. COOK, PhD TO ITS BOARD OF DIRECTORS Research Triangle Park, NC
FENNEC APPOINTS JODI A. COOK, PhD TO ITS BOARD OF DIRECTORS Research Triangle Park, NC, September 24, 2019 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosul
Read more →FENCFENNEC APPOINTS SHUBH GOEL AS CHIEF COMMERCIAL OFFICER Seasoned commercial leader to lead the anticipated launch of PEDMARK TM Research Triangle Park, NC
APPOINTS SHUBH GOEL AS CHIEF COMMERCIAL OFFICER Seasoned commercial leader to lead the anticipated launch of PEDMARKTM Research Triangle Park, NC, September 9, 2019 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the develo
Read more →FENCFENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS Anticipate PEDMARK TM New Drug Application (NDA) completion by early 2020 Strong financial position with $17.5 million in cash and no de
FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS Research Triangle Park, NC, August 9, 2019 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulati
Read more →FENCFENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS Targeting New Drug Application to U.S. FDA for PEDMARK TM in late 2019 to early 2020 Strong financial position with $20.2 million in cash
FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS Research Triangle Park, NC, May 9, 2019 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation o
Read more →FENCUniversity Avenue, 8th floor Date
100 University Avenue, 8th floor Date: April 18, 2019 Toronto ON, M5J 2Y1 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: FENNEC PHARMACEUTICALS INC. We advise of the following with respect to the upcoming Meeting of Security Holders for the
Read more →FENCFENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2018 FINANCIAL RESULTS Initiated rolling New Drug Application to U.S. FDA for PEDMARK TM Secured $12. 5 million debt financing to support a potential commercial l
FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2018 FINANCIAL RESULTS Research Triangle Park, NC, March 13, 2019 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES $12.5 MILLION DEBT FINANCING WITH BRIDGE BANK Research Triangle Park, NC
FENNEC PHARMACEUTICALS ANNOUNCES $12.5 MILLION DEBT FINANCING WITH BRIDGE BANK Research Triangle Park, NC, February 4, 2019 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation
Read more →FENCFennec Pharmaceuticals Initiates Rolling New Drug Application to U.s. Food and Drug Administration for PEDMARK™
PEDMARKTM is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumors. RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceutical
Read more →FENCFennec Pharmaceuticals Announces Scientific Symposium on Ototoxicity in Pediatric Cancer Patients at the 50th Congress of the International Society of Pediatric Oncology (SIOP) 2018 Meeting
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induce
Read more →FENCFennec Provides Business Update and Announces Third Quarter 2018 Financial Results
Positive Opinion on the Pediatric Investigation Plan from EMA for PEDMARKTM Targeting US approval of PEDMARKTM in the second half of 2019 Strong financial position with $24.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Fennec Pha
Read more →FENCFennec to Present at Cantor Fitzgerald Global Healthcare Conference on October 1, 2018 in New York City
RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induc
Read more →FENCFennec Provides Business Update and Announces Second Quarter 2018 Financial Results
Publication of PEDMARKTM SIOPEL 6 Clinical Data in The New England Journal of Medicine Joined Russell 3000 Index Strong financial position with $25.6 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ
Read more →FENCFennec Pharmaceuticals Receives Positive Opinion on the Pediatric Investigation Plan From European Medicines Agency for PEDMARK(TM) and Confirmation of Eligibility for a Pediatric Use Marketing Authorization
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the Company’s pediatric
Read more →FENCFennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine
SIOPEL 6 met primary endpoint (p=0.002) 48% reduction in the incidence of hearing loss No evidence of tumor protection RESEARCH TRIANGLE PARK, N.C., June 21, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focuse
Read more →FENCFennec Pharmaceuticals Set to Join Russell 3000 Index Research Triangle Park, NC
Fennec Pharmaceuticals Set to Join Russell Triangle Park, NC, June 11, 2018 - Fennec Pharmaceuticals Inc. (NASDAQ: FENC, TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention
Read more →FENCFennec Provides Business Update and Announces First Quarter 2018 Financial Results
PEDMARKTM granted Breakthrough Therapy and Fast Track Designations by FDA Actively preparing for NDA submission later this year Strong financial position with $26.7 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 14, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceutical
Read more →FENCFENNEC PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR PEDMARK Research Triangle Park, NC
FENNEC PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR PEDMARK Research Triangle Park, NC, March 27, 2018 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration
Read more →FENCFennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results
Phase 3 SIOPEL 6 study met primary endpoint (p=0.0033) NASDAQ listing in September 2017 Two equity financings completed Strong financial position at year end with $28.3 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., March 26, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmac
Read more →FENCFENNEC PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION BY FDA FOR PEDMARK Research Triangle Park, NC
FENNEC PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION BY FDA FOR PEDMARK Research Triangle Park, NC, March 21, 2018 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has
Read more →FENCFennec Provides Business Update And Reports Third Quarter 2017 Results
During the third quarter, the Company announced positive results from its Phase 3 SIOPEL 6 Study Study met primary endpoint (p=0.0033) indicating a significant reduction in cisplatin induced hearing loss without any evidence of tumor protection in patients with Standard Risk Hep
Read more →FENCFENNEC ANNOUNCES POSITIVE RESULTS FROM PHASE 3 SIOPEL 6 STUDY ON PEDMARK TM (sodium thiosulfate) PRESENTED AT THE 49 TH CONGRESS OF THE INTERNATIONAL SOCIETY OF PEDIATRIC ONCOLOGY (SIOP) 2017 MEETING Study met primary en
FENNEC ANNOUNCES POSITIVE RESULTS FROM PHASE 3 SIOPEL 6 STUDY ON PEDMARKTM (sodium thiosulfate) PRESENTED AT THE 49TH CONGRESS OF THE INTERNATIONAL SOCIETY OF PEDIATRIC ONCOLOGY (SIOP) 2017 MEETING Triangle Park, NC, October 16, 2017- Fennec Pharmaceuticals Inc. (NASDAQ: FENC,
Read more →FENCFennec to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017 in New York City
RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals, Inc. (NASDAQ:FENC) (TSX:FRX), today announced that Rosty Raykov, CEO of Fennec, will be presenting at the Cantor Fitzgerald Global Healthcare Conference in New York on September 27 at 4:00 pm
Read more →FENCFennec Announces Preliminary Results of SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) to be Presented at the 49TH Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting
SIOPEL 6 shows that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumor protection Among the first 94 evaluable patients, hearing loss occurred in 29/44=65.9% under Cisplatin Arm and in 19/50=38.0
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES LISTING ON THE NASDAQ CAPITAL MARKET Trading on Nasdaq under the symbol FENC is expected to commence on
FENNEC PHARMACEUTICALS ANNOUNCES LISTING ON THE NASDAQ CAPITAL MARKET Trading on Nasdaq under the symbol "FENC" is expected to commence on September 13, 2017 Research Triangle Park, NC, September 11, 2017 - Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty ph
Read more →FENCFennec Pharmaceuticals Announces Listing on the Nasdaq Capital Market
RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (TSX:FRX), (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patient
Read more →FENCFennec Provides Corporate Update and Announces Second Quarter 2017 Results
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Aug. 11, 2017) - Fennec Pharmaceuticals Inc. (TSX:FRX) (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric p
Read more →FENCFENNEC ANNOUNCES $7.6 MILLION PRIVATE PLACEMENT OF COMMON SHARES LED BY VENBIO SELECT ADVISOR Research Triangle Park, NC
FENNEC ANNOUNCES $7.6 MILLION PRIVATE PLACEMENT OF COMMON SHARES LED BY VENBIO SELECT ADVISOR Research Triangle Park, NC, June 8, 2017 - Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the develop
Read more →FENCFennec Announces Launch of European Named Patient Programme for Sodium Thiosulfate for Pediatric Patients With Standard Risk Hepatoblastoma
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 30, 2017) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric pat
Read more →FENCFennec Provides Corporate Update and Announces First Quarter 2017 Results
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 12, 2017) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric pat
Read more →FENCFennec to Present at Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - April 27, 2017) - Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today announced that Rosty Raykov, CEO of Fennec, will be presenting at the PIONEERS 2017 Joseph Gunnar Conference on Tuesday, May 2 at 2:00 PM ET in the
Read more →FENCFennec Provides Corporate Update and Announces Fiscal Year Ended December 31, 2016 Financial Results
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - March 30, 2017) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric p
Read more →FENCFennec to Present at 19th Annual BIO CEO & Investor Conference
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Feb. 9, 2017) - Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the 19th BIO CEO & Investor Conference on Monday, February 13, 2017 at 1:30 PM ET at the W
Read more →FENCFennec Announces the Lancet Oncology Publication of Children's Oncology Group Study of Sodium Thiosulfate
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Dec. 1, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX) (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric pa
Read more →FENCFennec Announces Repricing of Warrants
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Nov. 15, 2016) - Fennec Pharmaceuticals Inc. (the "Company" or "Fennec") (TSX:FRX)(OTCQB:FENCF) announced today that its board of directors has approved an amendment to the exercise price of the outstanding 366,133 common sha
Read more →FENCFennec Provides Corporate Update and Announces Third Quarter 2016 Results
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Nov. 14, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric pa
Read more →FENCFennec Announces Update of SIOPEL 6 Study on Sodium Thiosulfate (STS) Presented at the International Society of Paediatric Oncology (SIOP) 2016 Meeting
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Oct. 24, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric pa
Read more →FENCFennec to Present at Rodman & Renshaw 18th Annual Global Investment Conference in New York on September 13, 2016
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Sept. 8, 2016) - Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF) today announced that Rosty Raykov, CEO of Fennec, will present at the Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwrigh
Read more →FENCFennec Provides Corporate Update and Announces Second Quarter 2016 Results
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Aug. 12, 2016) - SIOPEL 6 interim results presented in oral presentation at ASCO 2016 confirms no evidence of tumor protection and is consistent with previous updates. Initial hearing efficacy data are "encouraging" with fin
Read more →FENCFENNEC ANNOUNCES APPOINTMENT OF MARCO BRUGHERA TO THE BOARD OF DIRECTORS Research Triangle Park, NC
FENNEC ANNOUNCES APPOINTMENT OF MARCO BRUGHERA TO THE BOARD OF DIRECTORS Research Triangle Park, NC, August 11, 2016 - Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the preve
Read more →FENCFennec to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference in New York on July 13, 2016
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - July 6, 2016) - Fennec Pharmaceuticals, Inc. (TSX:FRX) (OTCQB:FENCF), today announced that the Company will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York City at 10:45 AM EDT on Wednesday, July
Read more →FENCFENNEC ANNOUNCES INTERIM RESULTS OF SIOPEL 6 STUDY ON SODIUM THIOSULFATE (STS) PRESENTED AT THE AMERICAN ASSOCIATION OF CLINICAL ONCOLOGY (ASCO) 2016 MEETING No difference in Event free Survival (EFS) and Overall Surviva
FENNEC ANNOUNCES INTERIM RESULTS OF SIOPEL THIOSULFATE (STS) PRESENTED AT THE AMERICAN ASSOCIATION OF CLINICAL ONCOLOGY (ASCO) 2016 MEETING Research Triangle Park, NC, June 6, 2016 - Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focu
Read more →FENCFennec Announces Upcoming Events and Presentations
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 18, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced
Read more →FENCFENNEC ANNOUNCES SECOND CLOSING OF PRIVATE PLACEMENT Research Triangle Park, NC
FENNEC ANNOUNCES SECOND CLOSING OF PRIVATE Research Triangle Park, NC, May 16, 2016 - Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention
Read more →FENCFennec Provides Corporate Update and Announces First Quarter 2016 Results
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 12, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric pat
Read more →FENCFennec Announces Sodium Thiosulfate Presentation for Prevention of Ototoxicity in Children at ASCO Meeting
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - April 20, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induce
Read more →FENCFENNEC ANNOUNCES $5.0 MILLION PRIVATE
FENNEC ANNOUNCES $5.0 MILLION PRIVATE PLACEMENT OF COMMON SHARES BY SIGMA TAU FINANZIARIA Research Triangle Park, NC, April 8, 2016 - Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the developmen
Read more →FENCFennec Announces $5.0 Million Private Placement of Common Shares by Sigma Tau Finanziaria
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - April 8, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced
Read more →FENCFennec Provides Corporate Update and Announces Fiscal Year Ended December 31, 2015 Financial Results
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - March 28, 2016) - Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric
Read more →FENCFENNEC ANNOUNCES NEW CHAIRMAN OF THE BOARD Research Triangle Park, NC
FENNEC ANNOUNCES NEW CHAIRMAN OF THE Research Triangle Park, NC, December 9, 2015 - Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicit
Read more →FENCFennec Announces New Chairman of the Board
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Dec. 9, 2015) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric pa
Read more →FENCFennec Provides Corporate Update and Announces Third Quarter 2015 Financial Results
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Nov. 12, 2015) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric pa
Read more →FENCFennec to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York on September 10, 2015
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Sept. 3, 2015) - Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the Rodman & Renshaw 17th Annual Global Investment Conference in New York City at 5:05 ED
Read more →FENCFennec Provides Corporate Update and Announces Second Quarter 2015 Financial Results
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Aug. 11, 2015) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric pa
Read more →FENCFennec Announces Presentation of Positive Interim Sodium Thiosulfate Phase III Safety Data at the 2015 ASCO Annual Meeting
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 31, 2015) - Fennec Pharmaceuticals, Inc. (TSX:FRX) (OTCQB:FENCF), announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label r
Read more →FENCFennec to Present at the Jefferies 2015 Global Healthcare Conference
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 29, 2015) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) today announced that it will present at the Jefferies 2015 Global Healthcare Conference being held in New York City. Rosty Raykov, CEO, will provide an overvi
Read more →FENCFennec Provides Corporate Update and First Quarter Ended March 31, 2015 Financial Results
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 15, 2015) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric pat
Read more →FENCFennec Announces Availability of Siopel 6 Study Abstract for ASCO 2015 Meeting
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 14, 2015) - Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today announced that sodium thiosulfate (STS) will be featured in the abstract titled "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised
Read more →FENCFennec Pharmaceuticals Announces the Exercise of Warrants by the Company's Largest Shareholder and Provides Updated Corporate Capital Structure
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 4, 2015) - Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today reported that Southpoint Master Fund, LP ("Southpoint"), the Company's largest shareholder with 36.6% of Fennec's issued and outstanding shares has exe
Read more →FENCAdherex Announces Share Consolidation, Name Change and Trading Symbol Change - Research Triangle Park, NC
Announces Share Consolidation, Name Change and Trading Symbol Change - Research Triangle Park, NC - September 3, 2014 - Adherex Technologies Inc. (TSX:AHX)(OTCQB:ADHXF) (the "Company") announced today that it gave effect to the consolidation of its outstanding share capital on
Read more →FENCADHEREX ANNOUNCES results from two Sodium Thiosulfate phase 3 STUDIES PRESENTed AT the 50 TH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (asco) MEETING - COG STUDY ACCL0431 meets primary endpoint for prevention of cisplatin-in
ANNOUNCES results from two Sodium Thiosulfate phase 3 STUDIES PRESENTed AT the 50TH AMERICAN SOCIETY OF CLINICAL STUDY ACCL0431 meets primary endpoint for prevention of cisplatin-induced hearing loss in children -SIOPEL 6 Data Monitoring Committee recommends continuation of s
Read more →FENCAdherex Appoints Two Independent Directors Research Triangle Park, NC - (Marketwire)
Adherex Appoints Two Independent Directors Research Triangle Park, NC - (Marketwire) - April 28, 2014 - Adherex Technologies, Inc. (TSX:AHX, OTC: ADHXF) today announced the appointment of Dr. Khalid Islam and Adrian Haigh to the Company's Board of Directors, effective immediat
Read more →FENCADHEREX ANNOUNCES two Sodium Thiosulfate PRESENTATIONS For Prevention of Ototoxicity in children at asco meeting - COG STUDY ACCL0431 oral presentation for hearing protection in rare childhood cancers -SIOPEL 6 poster pr
ANNOUNCES two Sodium Thiosulfate PRESENTATIONS For Prevention of Ototoxicity in children at asco meeting STUDY ACCL0431 oral presentation for hearing protection in rare childhood cancers -SIOPEL 6 poster presentation for hearing protection in standard risk hepatoblastoma Res
Read more →FENCADHEREX ANNOUNCES Sodium thiosulfate CLINICAL STUDY UPDATE Research Triangle Park, NC - (Marketwire) - 02/26/14 - Adherex Technologies, Inc. (TSX:AHX, OTC: ADHXF) today announced that the Children's Oncology Group (COG),
Sodium thiosulfate CLINICAL STUDY UPDATE Research Triangle Park, NC - (Marketwire) - 02/26/14 - Adherex Technologies, Inc. (TSX:AHX, OTC: ADHXF) today announced that the Children's Oncology Group (COG), posted top line results on http://clinicaltrials.gov/ under Study ACCL0431
Read more →FENCADHEREX ANNOUNCES CLOSING OF PRIVATE PLACEMENT Research Triangle Park, NC
ADHEREX ANNOUNCES CLOSING OF PRIVATE Research Triangle Park, NC, November 22, 2013 - Adherex Technologies Inc. (the "Company" or "Adherex") (TSX: AXH, OTCQB: ADHXF), announced today that it has completed the previously-announced non-brokered private placement (the "Offering")
Read more →FENCADHEREX REPORTS RECENT DEVELOPMENTS AND THIRD QUARTER SEPTEMBER 30, 2013 FINANCIAL RESULTS Proposed fully subscribed above market financing of $1.6 mln Adherex to obtain and analyze clinical data from Sodium Thiosulfate
ADHEREX REPORTS RECENT DEVELOPMENTS AND THIRD QUARTER SEPTEMBER 30, 2013 FINANCIAL RESULTS Research Triangle Park, NC, November 15, 2013 - - Adherex Technologies Inc. (TSX: AXH, OTCQB: ADHXF), today reported its financial results and recent developments for the third quarter
Read more →FENCAdherex Announces Updated Guidance for Sodium Thiosulfate (STS) Results Research Triangle Park, NC
Adherex Announces Updated Guidance for Sodium Thiosulfate (STS) Results Research Triangle Park, NC, May 23, 2013 - Adherex Technologies Inc. (TSX:AHX, OTCQB: ADHXF), today announced that the results from Clinical Oncology Group (COG) Study ACCL0431, a phase 3 clinical study e
Read more →FENCAdherex Announces Corporate Update Research Triangle Park, NC
Adherex Announces Corporate Update Research Triangle Park, NC, August 15, 2013 - Adherex Technologies Inc. (TSX:AHX, OTC: ADHXF) announced today that David Lieberman has resigned from the Board of Directors. Rosty Raykov, CEO and a director of Adherex, will assume the role of
Read more →FENCADHEREX REPORTS FEEDBACK FROM THE FDA FROM END OF PHASE 2 MEETING Research Triangle Park, NC
ADHEREX REPORTS FEEDBACK FROM THE FDA FROM END OF PHASE 2 MEETING Research Triangle Park, NC, May 23, 2013 - Adherex Technologies Inc. (TSX:AHX, OTCQB: ADHXF), today announced that it has received feedback from the FDA at an End-of-Phase 2 meeting held yesterday. During the F
Read more →FENCADHEREX ANNOUNCES COMPLETION OF PATIENT ENROLLMENT AND MAINTAINS TSX LISTING STATUS Research Triangle Park, NC
ADHEREX ANNOUNCES COMPLETION OF PATIENT ENROLLMENT AND MAINTAINS TSX LISTING STATUS Research Triangle Park, NC, January 7, 2013 - Adherex Technologies Inc. (TSX: AHX, OTCQB: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, is pl
Read more →FENCAdherex Reports Positive Preliminary Interim Phase II Results for Eniluracil plus 5- Fluorouracil and Leucovorin at the CTRC-AACR San Antonio Breast Cancer Symposium Patients who had rapid disease progression on capecita
Adherex Reports Positive Preliminary Interim Phase II Results for Eniluracil plus 5- Fluorouracil and at the CTRC-AACR San Antonio Breast Cancer Patients who had rapid disease progression on capecitabine treatment1 (N=9) and crossed over to take eniluracil/5-FU/leucovorin (E
Read more →FENCAbout Adherex Technologies, Inc. Adherex Technologies Inc. is a biopharmaceutical company focused on the development of Eniluracil plus 5-Fluorouracil (5-FU) and Leucovorin. The Company is in the process of completing en
Adherex Comments on Remedial Delisting Review Initiated by the Toronto Stock Exchange Research Triangle Park, NC, September 18, 2012 - Adherex Technologies Inc. (TSX:AHX, OTC: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, ann
Read more →FENCAdherex to Present at Rodman & Renshaw
Adherex to Present at Rodman & Renshaw Annual Global Investment Conference Research Triangle Park, NC, September 4, 2012 - Adherex Technologies Inc. (TSX:AHX, Pink Sheets: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, announc
Read more →FENCAbout Metastatic Breast Cancer Breast cancer is the second leading cause of cancer related death among women, according to the National Cancer Institute. In 2010, NCI estimated that 207,090 women were diagnosed with brea
Adherex Provides Patient Enrollment Update for Phase 2 Study of Eniluracil in Metastatic Breast Cancer Research Triangle Park, NC, January 9, 2012 - Adherex Technologies Inc. (TSX:AHX, Pink Sheets: ADHXF), a biopharmaceutical company focused on the development of Eniluracil plu
Read more →FENCADHEREX REPORTS MEETING WITH FDA'S PEDIATRIC SUBCOMMITTEE OF THE ONCOLOGIC DRUGS ADVISORY COMMITTEE ON THE DEVELOPMENT OF SODIUM THIOSULFATE INJECTION Research Triangle Park, NC
ADHEREX REPORTS MEETING WITH FDA'S PEDIATRIC SUBCOMMITTEE OF THE ONCOLOGIC DRUGS ADVISORY COMMITTEE ON THE DEVELOPMENT OF SODIUM THIOSULFATE INJECTION Research Triangle Park, NC, October 7, 2011 - Adherex Technologies Inc. (TSX:AHX, Pink Sheets: ADHXF), a biopharmaceutical com
Read more →FENCADHEREX ANNOUNCES COMPLETION OF REVERSE STOCK SPLIT AND CONTINUANCE TO BRITISH COLUMBIA Research Triangle Park, NC
ADHEREX ANNOUNCES COMPLETION OF REVERSE STOCK SPLIT AND CONTINUANCE TO BRITISH COLUMBIA Research Triangle Park, NC, August 25, 2011 - Adherex Technologies Inc. (TSX:AHX, Pink Sheets: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil,
Read more →FENCADHEREX RESPONDS TO STOCK TRADING ACTIVITY Chapel Hill, NC
RESPONDS TO STOCK TRADING ACTIVITY Chapel Hill, NC, December 17, 2010 - - Adherex Technologies Inc. (TSX:AHX, Pink Sheets: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, is responding to a request from the Investment Industry
Read more →FENCADHEREX REPORTS SECOND QUARTER 2010 FINANCIAL RESULTS Chapel Hill, NC
REPORTS SECOND QUARTER 2010 FINANCIAL RESULTS Chapel Hill, NC, August 13, 2010 - Adherex Technologies Inc. (TSX:AHX, Pink Sheets: ADHXF), a biopharmaceutical company dedicated to providing innovative therapies that improve the life of cancer patients, today reported its finan
Read more →FENCAdherex Announces First Closing of Private Placement Chapel Hill, NC
Adherex Announces First Closing of Private Placement Chapel Hill, NC, April 30, 2010 - - Adherex Technologies Inc. (TSX:AHX), announced that it has completed a first closing of the previously announced non-brokered private placement ("Private Placement") of 240,066,664 units, at
Read more →FENCAdherex Announces Additional Financing Chapel Hill, NC
Adherex Announces Additional Financing Chapel Hill, NC, April 20, 2010 - - Adherex Technologies Inc. (TSX:AHX), announces today that it has entered into agreements with Southpoint Capital Advisors LP ("Southpoint"), Adherex's largest shareholder, and certain other investors, for
Read more →FENCADHEREX ANNOUNCES A NEW CORPORATE DIRECTION FOR THE COMPANY Research Triangle Park, NC
ADHEREX ANNOUNCES A NEW CORPORATE DIRECTION FOR THE Research Triangle Park, NC, July 7, 2009 - - Adherex Technologies Inc. (TSX:AHX) announced today, the Company has decided to focus its remaining resources on the development of eniluracil. This decision was reached after caref
Read more →FENCADHEREX FILES TO DELIST FROM THE AMEX Stock Continues to Trade on TSX Research Triangle Park, NC
ADHEREX FILES TO DELIST FROM THE AMEX Stock Continues to Trade on TSX Research Triangle Park, NC, January 9, 2009 Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company dedicated to solving problems for patients with cancer, today announced that the Company
Read more →FENCAdherex Receives AMEX Delisting Notice Implements Success-Based Incentive Program Research Triangle Park, NC
Adherex Receives AMEX Delisting Notice Implements Success-Based Incentive Program Research Triangle Park, NC, December 10, 2008 Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company dedicated to solving problems for patients with cancer, today reported tha
Read more →FENCADHEREX ANNOUNCES AGREEMENT FOR STS PHASE III DATA Research Triangle Park, NC
ADHEREX ANNOUNCES AGREEMENT FOR STS PHASE III DATA Research Triangle Park, NC, May 14, 2008 - Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today a license agreement with the Netherland
Read more →FENCAdherex Reports First Quarter 2008 Financial Results Research Triangle Park, NC
Adherex Reports First Quarter 2008 Financial Results Research Triangle Park, NC, May 13, 2008 Adherex Technologies Inc. (AMEX:ADH, TSX: AHX), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today its financial results for the first qu
Read more →FENCADHEREX REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS Research Triangle Park, NC
ADHEREX REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS Research Triangle Park, NC, November 7, 2007 Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today reported its financial results for t
Read more →FENCADHEREX REPORTS 2006 FISCAL RESULTS Research Triangle Park, NC
ADHEREX REPORTS 2006 FISCAL RESULTS Research Triangle Park, NC, March 26, 2007 Adherex Technologies Inc. (AMEX:ADH, TSX: AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today reported its financial results for the twelve-month fi
Read more →FENCADHEREX COMPLETES US$25 MILLION PUBLIC FINANCING Research Triangle Park, NC
ADHEREX COMPLETES US$25 MILLION PUBLIC FINANCING Research Triangle Park, NC, February 21, 2007 Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that it has completed the pre
Read more →FENCADHEREX ANNOUNCES FILING OF FINAL PROSPECTUS Research Triangle Park, NC
ADHEREX ANNOUNCES FILING OF FINAL PROSPECTUS Research Triangle Park, NC, February 14, 2007 Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that it has filed a final short f
Read more →FENCADHEREX ANNOUNCES EQUITY OFFERING UP TO US$25 MILLION Minimum of US$10 million in gross proceeds and a maximum of US$25 million Research Triangle Park, NC
ADHEREX ANNOUNCES EQUITY OFFERING UP TO US$25 MILLION Minimum of US$10 million in gross proceeds and a maximum of Research Triangle Park, NC, January 19, 2007 Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products
Read more →FENCADHEREX BUYS OUT ENILURACIL DEVELOPMENT OPTIONS FROM GLAXOSMITHKLINE Research Triangle Park, NC
ADHEREX BUYS OUT ENILURACIL DEVELOPMENT OPTIONS FROM GLAXOSMITHKLINE Research Triangle Park, NC, January 18, 2007 Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced it has ame
Read more →FENCADHEREX REPORTS THIRD QUARTER 2006 FINANCIAL RESULTS Research Triangle Park, NC
ADHEREX REPORTS THIRD QUARTER 2006 FINANCIAL RESULTS Research Triangle Park, NC, November 13, 2006 Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today reported its financial results for
Read more →FENCADHEREX REPORTS SECOND QUARTER 2006 FINANCIAL RESULTS Research Triangle Park, NC
ADHEREX REPORTS SECOND QUARTER 2006 FINANCIAL RESULTS Research Triangle Park, NC, August 9, 2006 Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today reported its financial results for th
Read more →FENCADHEREX REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS Research Triangle Park, NC
ADHEREX REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS Research Triangle Park, NC, May 15, 2006 Adherex Technologies Inc. (AMEX:ADH, TSX: AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today reported its financial results for the
Read more →FENCADHEREX ANNOUNCES US$6.5 MILLION PRIVATE PLACEMENT Research Triangle Park, NC
ADHEREX ANNOUNCES US$6.5 MILLION PRIVATE PLACEMENT Research Triangle Park, NC, May 4, 2006 Adherex Technologies Inc. (AMEX: ADH; TSX: AHX), a biopharmaceutical company with a portfolio of oncology products under development, today announced that it has received firm commitments
Read more →FENCA MESSAGE TO OUR SHAREHOLDERS This past year was highlighted by the presentation of important safety and promising efficacy data for ADH-1, the advancement of ADH-1 into Phase II trials and the from GlaxoSmithKline (GSK)
This past year was highlighted by the presentation of important safety and promising efficacy data for ADH-1, the advancement of ADH-1 into Phase II trials and the from GlaxoSmithKline (GSK) of the potential blockbuster oncology drug, eniluracil. While 2005 has been a disappoint
Read more →FENCADHEREX REPORTS THIRD QUARTER 2005 FINANCIAL RESULTS Research Triangle Park, NC
ADHEREX REPORTS THIRD QUARTER 2005 FINANCIAL RESULTS Research Triangle Park, NC, November 7, 2005 Adherex Technologies Inc. (AMEX:ADH, TSX: AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today reported its financial results for
Read more →FENCADHEREX REPORTS SECOND QUARTER 2005 FINANCIAL RESULTS Research Triangle Park, NC
ADHEREX REPORTS SECOND QUARTER 2005 FINANCIAL RESULTS Research Triangle Park, NC, August 10, 2005 Adherex Technologies Inc. (AMEX:ADH, TSX: AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today reported its financial results for
Read more →FENCADHEREX TECHNOLOGIES INC. Annual and Special Meeting of Shareholders
ADHEREX TECHNOLOGIES INC. Annual and Special Meeting of Shareholders April 29, 2005 TO: Superintendent of Brokers, British Columbia Alberta Securities Commission Saskatchewan Securities Commission Manitoba Securities Commission Ontario Securities Commission Autorit d
Read more →FENCADHEREX REPORTS FIRST QUARTER 2005 FINANCIAL RESULTS Research Triangle Park, NC
ADHEREX REPORTS FIRST QUARTER 2005 FINANCIAL RESULTS Research Triangle Park, NC, May 10, 2005 Adherex Technologies Inc. (AMEX:ADH, TSX: AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today reported its financial results for the
Read more →FENCADHEREX REPORTS 2004 SIX-MONTH FISCAL TRANSITION RESULTS Research Triangle Park, NC
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated: March 21, 2005 Commission File Number 001-32295 ADHEREX TECHNOLOGIES INC. (Translation of registra
Read more →FENCChairman s Letter Adherex is continuing our efforts to build a clinical drug development enterprise focused on bringing our drugs to market as rapidly as possible and developing novel solutions to the significant unmet n
Adherex is continuing our efforts to build a clinical drug development enterprise focused on bringing our drugs to market as rapidly as possible and developing novel solutions to the significant unmet needs of cancer patients. We have come a long way over the past six months, de
Read more →FENCADHEREX LOGO APPEARS HERE] PRESS RELEASE ADHEREX RECEIVES APPROVAL FOR AMEX LISTING - Trading expected to begin
[ADHEREX LOGO APPEARS HERE] ADHEREX RECEIVES APPROVAL FOR AMEX LISTING - Trading expected to begin November 12, 2004 under the symbol ADH - Triangle Park, NC, November 10, 2004 Adherex Technologies Inc. (TSX: AHX), a biopharmaceutical company with a broad portfolio of oncolog
Read more →Competitive Position
How FENC ranks across every disease it competes inCompetitive Position is a premium feature
See how FENC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial